Multicentre evaluation of the Tosoh HbA1c G8 analyser

Chapelle, Jean-Paul; Teixeira, Jelda; Maisin, Diane; Assink, Hans; Barla, Gerhard; Stroobants, An K.; Delzenne, B.; Eshof, Wouters van den

doi:10.1515/cclm.2010.062

Cited by 41 publications

(24 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…GHb levels were determined by the following five methods: HPLC method using ADAMS-A 1C HA-8160 (Arkray, Kyoto, Japan) 13 and that using HLC-723 G8 (Tosoh, Tokyo, Japan), 14 LA method (RAPIDIA Auto HbA 1C -L; Fujirebio, Tokyo, Japan), 15 enzymatic method (Nordia-N HbA 1C ; Sekisui Medical, Tokyo, Japan) 16 and affinity method (GHb V, affinity mode; Tosoh). 17,18 All these methods were corrected by using Japan Diabetes Society lot 2 GHb 19 and the normal control range of GHb for adults is from 4.3 to 5.3%.…”

Section: Discussionmentioning

confidence: 99%

Measurement of glycated hemoglobin and glycated albumin in umbilical cord: evaluation of the glycemic control indicators in neonates

et al. 2010

View full text Add to dashboard Cite

Objective: As neonatal blood contains a high proportion of fetal hemoglobin (HbF), it is difficult to use high-performance liquid chromatography (HPLC) method, latex-immunoturbidimetry (LA) method and enzymatic methods, which determine hemoglobin A 1C (HbA 1C ) in order to provide the glycemic control indicators of neonates. In this study, we evaluated glycated hemoglobin (GHb) and glycated albumin (GA) as appropriate indicators of the glycemic control in the neonatal period.Study Design: Umbilical cord blood samples collected during delivery were subjected to measurements of GHb (HPLC methods using two different instruments, LA method, enzymatic method and affinity method) and serum GA.Result: HbA 1C levels determined by the HPLC method, the LA method and the enzymatic method were as low as <3.0% in all the cases. Although GHb determined by the affinity method was 3.6 ± 0.2%, this method may not measure accurately the values of glycated HbF plus glycated HbA. Serum GA was 9.4 ± 1.1%. Conclusion:We speculate that serum GA, but not GHb, could be used as glycemic control indicators in neonates.

show abstract

Section: Discussionmentioning

confidence: 99%

Measurement of glycated hemoglobin and glycated albumin in umbilical cord: evaluation of the glycemic control indicators in neonates

et al. 2010

View full text Add to dashboard Cite

show abstract

“…At baseline and after 10 weeks of treatment, blood samples were collected at the outpatient clinic in the morning after overnight fasting for measurement of the following parameters: HbA 1c , 1,5-anhydro-D-glucitol (1,5-AG), glucose, insulin, glucagon, non-esterified fatty acid (NEFA), total cholesterol, TG, high-density lipoprotein cholesterol, apolipoprotein AI, apolipoprotein AII, apolipoprotein B (ApoB), apolipoprotein CII, apolipoprotein CIII, apolipoprotein E, apolipoprotein B48 (ApoB-48), remnantlike particle cholesterol (RLP-C), aspartate aminotransferase, alanine aminotransferase, and creatinine. A high-performance liquid chromatography (HLC-723 G8; Tosoh, Tokyo, Japan) system was used to measure HbA 1c according to the International Federation of Clinical Chemistry reference standard methods [12], and HbA 1c values are therefore shown as National Glycohemoglobin Standardization Program equivalent values in this study. 1,5-AG levels were measured using the enzymatic method with the "Lana AG" column-enzyme assay kit (Nippon Kayaku Co. Ltd., Tokyo, Japan) [13].…”

Section: Measurementsmentioning

confidence: 99%

Effects of miglitol <i>versus</i> sitagliptin on postprandial glucose and lipoprotein metabolism in patients with type 2 diabetes mellitus

et al. 2013

View full text Add to dashboard Cite

PostPrandial hyPerglycemia and hyperlipidemia have been shown to be risk factors for atherosclerosis [1][2][3]. Potential agents to target postprandial hyperglycemia and hyperlipidemia in patients with type 2 diabetes mellitus (T2DM) include α-glucosidase inhibitors (AGIs) and dipeptidyl peptidase (DPP)-4 inhibitors. Miglitol is an AGI that improves postprandial hyperglycemia and hyperlipidemia [4] abstract. Postprandial hyperglycemia and/or hyperlipidemia can contribute to development of atherosclerosis in patients with type 2 diabetes mellitus (T2DM). The objective of this study was to compare the effects of miglitol and sitagliptin on postprandial glucose and lipid metabolism in patients with T2DM. Thirty-five patients with T2DM were randomized to 2 groups receiving miglitol (150 mg/day) or sitagliptin (50 mg/day). Serum variables related to glucose and lipid metabolism were measured before and after treatment for 10 weeks and at 0, 60, and 120 min using a cookie-loading test (CLT). After 10 weeks of treatment, miglitol (n = 16) and sitagliptin (n = 18) caused a similarly significant decrease in hemoglobin A 1c (mean: 7.6% to 7.3% versus 8.0% to 7.6%) and a significant increase in fasting insulin levels, with a greater increase observed in the miglitol group than in the sitagliptin group (p=0.03). In addition, a significant decrease in the change in glucose levels after the CLT was observed in both groups, with a greater decrease observed in the miglitol group than in the sitagliptin group (p=0.02). The miglitol group also showed a greater decrease in the change in insulin levels after the CLT than the sitagliptin group (p<0.01). The lipid and lipoprotein levels did not show any significant differences between the groups after the CLT. Our results suggested that miglitol and sitagliptin treatment resulted in similar glycemic control but that a greater decrease in postprandial glucose and insulin levels was observed with miglitol compared with sitagliptin in patients with T2DM.

show abstract

“…Many new devices introduced on the market using different principles of HbA 1c measurement were scientifically evaluated: HPLC [134,135] , immunoassay [136] , enzymatic assay [137] and even capillary electrophoresis [138] which was previously considered unsuitable for routine HbA 1c assay [139] . Most of these methods showed improved performances in terms of precision and specificity.…”

Section: The Times Of Expansionmentioning

confidence: 99%

A history of HbA_1c through Clinical Chemistry and Laboratory Medicine

Gillery¹

2012

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

HbA 1c was discovered in the late 1960s and its use as marker of glycemic control has gradually increased over the course of the last four decades. Recognized as the gold standard of diabetic survey, this parameter was successfully implemented in clinical practice in the 1970s and 1980s and internationally standardized in the 1990s and 2000s. The use of standardized and well-controlled methods, with well-defined performance criteria, has recently opened new directions for HbA 1c use in patient care, e.g., for diabetes diagnosis. Many reports devoted to HbA 1c have been published in Clinical Chemistry and Laboratory Medicine (CCLM) journal. This review reminds the major steps of HbA 1c history, with a special emphasis on the contribution of CCLM in this field.

show abstract

Multicentre evaluation of the Tosoh HbA1c G8 analyser

Abstract: With respect to reproducibility, chromatographic resolution, speed of analysis and identification of Hb variants, the Tosoh G8 analyser can be considered to be state of the art.

Cited by 41 publications

References 22 publications

Measurement of glycated hemoglobin and glycated albumin in umbilical cord: evaluation of the glycemic control indicators in neonates

Measurement of glycated hemoglobin and glycated albumin in umbilical cord: evaluation of the glycemic control indicators in neonates

Effects of miglitol <i>versus</i> sitagliptin on postprandial glucose and lipoprotein metabolism in patients with type 2 diabetes mellitus

A history of HbA_1c through Clinical Chemistry and Laboratory Medicine

Contact Info

Product

Resources

About

Multicentre evaluation of the Tosoh HbA1c G8 analyser

Abstract: With respect to reproducibility, chromatographic resolution, speed of analysis and identification of Hb variants, the Tosoh G8 analyser can be considered to be state of the art.

Cited by 41 publications

References 22 publications

Measurement of glycated hemoglobin and glycated albumin in umbilical cord: evaluation of the glycemic control indicators in neonates

Measurement of glycated hemoglobin and glycated albumin in umbilical cord: evaluation of the glycemic control indicators in neonates

Effects of miglitol <i>versus</i> sitagliptin on postprandial glucose and lipoprotein metabolism in patients with type 2 diabetes mellitus

A history of HbA1c through Clinical Chemistry and Laboratory Medicine

Contact Info

Product

Resources

About

A history of HbA_1c through Clinical Chemistry and Laboratory Medicine